Medications That Cause Dry Mouth: Which Drug Classes and What to Do

Salivary glands are primarily controlled by the parasympathetic nervous system through muscarinic receptors. When these receptors are stimulated, glands produce watery, enzyme-rich saliva. Medications that block muscarinic receptors (anticholinergics) or that reduce the parasympathetic signal in other ways will proportionally reduce saliva output.

Other mechanisms include reduced blood flow to glands (alpha-adrenergic effects), diuretic effects that reduce total body water available for secretion, and direct glandular toxicity in some cases. Many drugs cause dry mouth through a combination of these mechanisms, which is why polypharmacy produces disproportionately severe xerostomia compared to any single drug taken alone.

The severity of dry mouth from a specific drug depends on the drug's anticholinergic potency, the dose, individual variation in receptor sensitivity, baseline salivary function (which declines with age), and what other medications are being taken simultaneously.

Drugs with direct anticholinergic activity are the most consistent culprits for significant dry mouth. Classic anticholinergics include bladder medications such as oxybutynin (Ditropan) and tolterodine (Detrol), which are prescribed for overactive bladder. These drugs are pharmacologically designed to block muscarinic receptors, which reduces unwanted bladder contractions but simultaneously reduces salivary secretion. Dry mouth is listed as the primary dose-limiting side effect of this entire drug class.

Tricyclic antidepressants (TCAs) such as amitriptyline, nortriptyline, and doxepin have substantial anticholinergic properties as part of their pharmacology. They are used for depression, neuropathic pain, and insomnia. Even at low doses used for pain management (10 to 25 mg nightly), TCAs can produce significant xerostomia in sensitive patients. Nortriptyline has somewhat lower anticholinergic burden than amitriptyline and is sometimes substituted for this reason.

First-generation antihistamines (diphenhydramine, chlorpheniramine, hydroxyzine) have significant anticholinergic properties. Diphenhydramine (Benadryl) is particularly problematic because it is widely available over the counter, found in many nighttime cold and allergy products, and taken by patients who do not realize it has strong anticholinergic effects. Regular use by older adults contributes significantly to their overall anticholinergic burden.

Selective serotonin reuptake inhibitors (SSRIs) such as sertraline, fluoxetine, and paroxetine cause dry mouth through a mechanism that is not purely anticholinergic. The serotonergic modulation of autonomic function affects salivary gland output, and some SSRIs have additional secondary receptor effects that contribute. Paroxetine has the highest anticholinergic activity among the SSRIs and is most consistently associated with xerostomia. Sertraline and escitalopram have lower anticholinergic burden.

Serotonin-norepinephrine reuptake inhibitors (SNRIs) such as venlafaxine and duloxetine also cause dry mouth, partly through their noradrenergic activity. The norepinephrine component increases sympathetic tone, which shifts saliva production toward thicker, more mucous-type secretions rather than the watery type, resulting in the sensation of dryness even when total volume is not dramatically reduced.

Atypical antipsychotics such as quetiapine, olanzapine, and risperidone vary in their anticholinergic profiles. Quetiapine and clozapine have substantial anticholinergic activity. These medications are increasingly used off-label for sleep, anxiety, and adjunctive depression treatment, increasing the population of patients exposed to their xerostomic effects.

Beta-blockers (atenolol, metoprolol, propranolol) cause dry mouth primarily through sympathetic blockade, which shifts the balance of autonomic control toward the parasympathetic side without increasing parasympathetic activity. The net effect is reduced salivary volume and, in some patients, altered saliva composition. The effect is generally milder than with anticholinergics.

Calcium channel blockers (amlodipine, nifedipine, diltiazem) cause dry mouth in a subset of patients and can produce gingival overgrowth (gum enlargement) as a separate effect in some individuals. The mechanism is not well characterized but may relate to reduced glandular blood flow.

Diuretics, both thiazides (hydrochlorothiazide) and loop diuretics (furosemide), reduce total body water content by increasing urinary output. This reduces the overall fluid available for salivary secretion, particularly in patients who do not adequately compensate with increased fluid intake. The xerostomia from diuretics is relatively straightforward volume depletion and can often be partially managed by increasing water intake.

Benzodiazepines (diazepam, lorazepam, clonazepam) and Z-drugs (zolpidem, eszopiclone) used for anxiety and sleep cause dry mouth through a combination of central nervous system depression reducing autonomic output and, in some cases, direct receptor effects. Patients taking these at night often wake with severe morning dry mouth.

Muscle relaxants with anticholinergic properties, such as cyclobenzaprine (Flexeril) and orphenadrine, are commonly prescribed for musculoskeletal pain and carry significant xerostomic potential. Scopolamine patches used for motion sickness or nausea are potent anticholinergics and will produce marked dry mouth with continued use.

Opioid analgesics cause dry mouth through central mechanisms that reduce parasympathetic output, and the effect scales with dose and duration. Patients on chronic opioid therapy for pain management frequently list dry mouth as a significant quality-of-life issue alongside constipation and other anticholinergic-like effects.

Second-generation antihistamines (cetirizine, loratadine, fexofenadine) have much lower anticholinergic profiles than first-generation agents, and dry mouth is significantly less common with these drugs. If a patient is using diphenhydramine regularly for allergy or sleep, switching to a second-generation antihistamine is often one of the easiest medication adjustments to reduce anticholinergic burden.

The most effective intervention is discussing medication adjustments with your prescribing physician or pharmacist. Not every xerostomic medication has an equivalent alternative, but many do. Substituting a TCA with an SNRI or SSRI with a lower anticholinergic profile, switching from a first-generation antihistamine to a second-generation one, or adjusting dosing times can produce meaningful improvement without sacrificing therapeutic benefit.

At your dental visits, inform your dentist of all medications and when they were started. A new medication that correlates with the onset of dry mouth symptoms or new cavities in unusual locations is a clinically significant finding. Dentists can calculate approximate anticholinergic burden using published scoring systems and identify when the medication list warrants physician review.

Dentally, patients on xerostomic medications need more aggressive preventive care: prescription fluoride toothpaste, more frequent professional cleanings, fluoride varnish at each visit, and monitoring for early decay and candidiasis. Artificial saliva products and salivary stimulants (sugarless xylitol gum, prescription pilocarpine if appropriate) can help. The goal is to compensate for the loss of saliva's protective functions until the medication situation can be optimized.